PRGO:NYE-Perrigo Company PLC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 23.51

Change

-0.83 (-3.41)%

Market Cap

N/A

Volume

1.79M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.91 (-1.15%)

USD 74.37B
HLN Haleon plc

-0.09 (-0.99%)

USD 42.79B
TAK Takeda Pharmaceutical Co Ltd A..

+0.05 (+0.38%)

USD 41.33B
RDY Dr. Reddy’s Laboratories Ltd..

-0.05 (-0.33%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

N/A

USD 5.65B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.13 (+1.68%)

USD 3.68B
BHC Bausch Health Companies Inc

+0.08 (+1.08%)

USD 2.91B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

+0.03 (+6.15%)

USD 1.96M

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
ION Proshares S&P Global Core.. 3.79 % 0.00 %

+0.34 (+1.30%)

USD 2.54M
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.24 (1.30%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-0.43 (1.30%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

+0.08 (+1.30%)

CAD 0.72B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 0.00 % 0.00 %

+0.19 (+1.30%)

CAD 0.01B
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.56% 14% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.56% 14% F 4% F
Trailing 12 Months  
Capital Gain -28.76% 20% F 7% C-
Dividend Return 3.35% 50% F 49% F
Total Return -25.41% 20% F 8% B-
Trailing 5 Years  
Capital Gain -60.49% 43% F 8% B-
Dividend Return 8.56% 40% F 26% F
Total Return -51.93% 43% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -13.15% 13% F 4% F
Dividend Return -10.74% 13% F 4% F
Total Return 2.41% 83% B 55% F
Risk Return Profile  
Volatility (Standard Deviation) 8.16% 100% F 84% B
Risk Adjusted Return -131.58% 7% C- N/A F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector